C1q: Complete Research Profile — Classical Complement Pathway Initiator, Microglial Synaptic Pruning, and Neuroinflammation Research (2026)

# C1q: Complete Research Profile — Classical Complement Pathway Initiator, Microglial Synaptic Pruning, and Neuroinflammation Research

Introduction

C1q is the recognition subunit of the classical complement pathway — the multimeric protein that binds antibody-antigen complexes, apoptotic cells, and other "eat me" signals to trigger downstream complement activation. For decades it was studied almost exclusively as an innate immune opsonin. That view changed decisively in 2007, when Beth Stevens and colleagues showed that C1q tags weak or inappropriate synapses in the developing central nervous system for removal by microglia, establishing complement as a core mechanism of activity-dependent circuit refinement (Stevens et al., 2007, Cell, PMID: 18083105). That single finding repositioned C1q from a purely peripheral immune molecule into one of the most actively studied proteins in neuroimmunology, with direct research relevance to brain aging, Alzheimer's disease models, and now oncology.

This profile covers C1q's molecular structure, its role in classical pathway activation, its expanding receptor biology, its function in synaptic pruning across development and aging, and its emerging roles outside the nervous system. This is a laboratory research reference — C1q and related complement reagents discussed here are Research Use Only (RUO) tools for in vitro and preclinical in vivo studies, not therapeutic agents.

Structure and Biosynthesis

C1q is an 18-chain glycoprotein assembled from six copies each of three distinct polypeptides — C1qA, C1qB, and C1qC — encoded by three tandem genes (C1QA, C1QB, C1QC) on chromosome 1p36.12. Each chain contains an N-terminal collagen-like triple-helical region and a C-terminal globular head domain (gC1q). Three chains (one A, one B, one C) associate to form a heterotrimeric subunit, and six of these subunits assemble into the intact molecule, producing the classic "bouquet of tulips" architecture: six collagen-like stalks converging at an N-terminal fibril-like structure, fanning out into six globular heads (Thielens et al., 2017, Molecular Immunology, PMID: 28601358).

C1q is synthesized primarily by macrophages, immature dendritic cells, and — critically for CNS research — microglia, the brain's resident macrophage-lineage cells. In blood, C1q circulates non-covalently associated with two serine protease zymogens, C1r and C1s, in a Ca²⁺-dependent C1 complex (C1qC1r₂C1s₂). The collagen-like stalk mediates this C1r/C1s association, while the globular heads mediate target recognition — a structure-function division that underlies nearly all of C1q's downstream signaling.

Classical Pathway Activation

Classical pathway activation begins when the gC1q globular heads engage a clustered activating surface — most canonically the Fc region of IgG or IgM bound to antigen, but also a wide range of "danger" and "altered-self" ligands including apoptotic cell membranes, pentraxins (CRP, serum amyloid P, PTX3), fibrillar β-amyloid, and certain bacterial and viral surfaces. Multivalent engagement of the C1q heads induces a conformational change in the collagen stalks that activates C1r, which in turn cleaves and activates C1s. Activated C1s then cleaves C4 and C2 to assemble the C3 convertase (C4b2a), driving the shared complement cascade toward C3 activation, opsonization, and — if amplified — the anaphylatoxins C3a and C5a and the terminal membrane attack complex. Researchers studying this axis alongside anaphylatoxin biology may find our C3a/C5a anaphylatoxin research profile useful for connecting initiation (C1q) to effector output (C3a/C5a).

C1q can also act completely independently of C1r/C1s proteolysis and the downstream cascade — a distinction that matters for interpreting research data, since many of C1q's non-canonical cellular effects (below) occur without complement activation at all.

C1q Receptors: Beyond Simple Opsonization

C1q signals through a surprisingly diverse receptor repertoire, each engaging a different structural region of the molecule:

• •cC1qR / calreticulin — binds the collagen-like region and cooperates with CD91 to mediate phagocytic uptake of C1q-opsonized apoptotic cells.
• •CD93 (C1qRp) — a type I transmembrane receptor implicated in enhancing phagocytosis of C1q-tagged particles.
• •gC1qR (p33/C1QBP) — binds the globular head domain; broadly expressed and implicated in inflammation, coagulation, and mitochondrial biology.
• •CR1 (CD35) — the classical complement receptor, binds C1q as well as C3b/C4b fragments.
• •LAIR-1 (CD305) — an inhibitory immunoreceptor of the Ig superfamily that recognizes GPO collagen motifs in the C1q collagen-like stalk. C1q-LAIR-1 engagement restrains dendritic cell differentiation and activation, providing a non-inflammatory, tolerogenic signaling arm distinct from classical opsonization (Son et al., 2012, PNAS, PMID: 23093673).

This receptor diversity explains why C1q research spans immunotolerance, phagocytic clearance, and neuroinflammation within a single molecule — the "which receptor, which cell type, which tissue" question is central to interpreting any C1q functional assay.

Microglial Synaptic Pruning: The Landmark Finding

The discovery that reframed C1q research came from the developing visual system. Stevens and colleagues showed that C1q and downstream C3 are localized to a subset of synapses in the postnatal retinogeniculate system, that mice lacking C1q or C3 fail to properly refine retinogeniculate connections, and that microglia — expressing the complement receptor CR3 (CD11b/CD18) — engulf C1q/C3-tagged synaptic material (Stevens et al., 2007, Cell, PMID: 18083105). This established a "tag and eat" model directly analogous to peripheral opsonophagocytosis, but repurposed for activity-dependent circuit sculpting: weaker, less-active synapses are preferentially complement-tagged and removed, while stronger synapses are spared.

This mechanism does not switch off after development. In the aging brain, C1q protein increases dramatically — by as much as several hundred-fold in some regions — with the earliest and steepest accumulation in the hippocampus, substantia nigra, and piriform cortex, regions with outsized relevance to neurodegenerative disease research (Stephan et al., 2013, Journal of Neuroscience, PMID: 23946404). C1q-deficient aged mice show enhanced synaptic plasticity and altered hippocampal circuit reorganization relative to wild-type littermates, suggesting that chronic complement tagging progressively constrains synaptic plasticity across the lifespan — a mechanistic bridge between normal aging and pathological synapse loss.

C1q in Neurodegeneration Research Models

Because C1q, C3, and CR3 form a synapse-elimination axis that is developmentally beneficial but can become pathologically reactivated, this pathway is heavily studied in mouse models of neurodegenerative disease. In amyloid-precursor-protein transgenic mice, C1q accumulates at synapses prior to plaque formation, and genetic or antibody-mediated blockade of C1q or C3 protects against early synapse loss — implicating the classical pathway as an upstream driver of synaptic vulnerability rather than a passive bystander of amyloid pathology (Hong et al., 2016, Science, PMID: 27033548). This finding sits directly alongside our existing research profiles on amyloid-beta (Aβ42/Aβ40) biology and alpha-synuclein aggregation: C1q-tagged synaptic engulfment is increasingly viewed in the literature as a shared downstream mechanism across multiple proteinopathy models, not a phenomenon unique to amyloid biology.

Microglial reactivity itself is governed by additional signaling axes worth cross-referencing — see our IL-34/CSF1R/PTPζ microglial biology profile for the trophic/homeostatic side of microglial regulation that operates alongside complement-driven phagocytic tagging, and our IL-1β/NLRP3 inflammasome profile for the pro-inflammatory cytokine axis frequently co-activated with complement in neuroinflammation research designs.

C1q Beyond the Nervous System

Tumor microenvironment biology. C1q is expressed locally by tumor-associated macrophages and activated fibroblasts in a range of solid tumors. Notably, this local C1q pool can promote cancer cell adhesion, migration, and proliferation through complement-activation-independent signaling — engaging cell-surface receptors directly rather than triggering the C1r/C1s cascade — reframing C1q as a potential stromal factor in tumor progression rather than solely a tumor-clearance opsonin (Bulla et al., 2016, Nature Communications, PMID: 26831747).

Apoptotic cell clearance and autoimmunity. C1q opsonizes apoptotic cell surfaces, promoting their "silent," non-inflammatory clearance by phagocytes. This function is so fundamental that hereditary C1q deficiency is one of the strongest single-gene risk factors for systemic lupus erythematosus in human genetics research, presumably because impaired clearance of apoptotic debris and nuclear autoantigens drives autoimmune priming — a frequently cited research model for studying the immunological consequences of defective efferocytosis.

Dendritic cell and tolerogenic signaling. Through LAIR-1 engagement, C1q restrains monocyte-derived dendritic cell differentiation and dampens TLR-driven activation, positioning it as a homeostatic "brake" on antigen-presenting cell maturation — a mechanism of interest in tolerance and autoimmunity research models.

C1q vs. Related Complement Recognition Molecules

C1q, MBL, and ficolins all initiate their respective activation pathways through structurally convergent but genetically distinct pattern-recognition strategies (collagen-domain oligomers in each case), while C3a and C5a are downstream proteolytic effector fragments rather than recognition molecules — see the C3a/C5a profile for the effector side of this cascade.

Research Methods for Studying C1q

• •ELISA and Western blot — standard quantification of C1q protein levels in serum, CSF, or tissue lysates; the primary method used to demonstrate age-dependent CNS C1q accumulation.
• •Immunohistochemistry/immunofluorescence — co-localization of C1q with synaptic markers (e.g., PSD-95, synaptophysin) and microglial markers (Iba1, CR3/CD11b) is the standard approach for synaptic-tagging studies.
• •Flow cytometry — used to quantify C1q binding to cell surfaces, apoptotic cell opsonization assays, and microglial CR3 expression; see our flow cytometry methods guide for panel design considerations applicable to complement-tagging assays.
• •Genetic knockout models — C1qa⁻/⁻ mice are the standard tool for isolating C1q-dependent phenotypes from the broader classical pathway, since loss of any A, B, or C chain abolishes assembly of the intact molecule.
• •Antibody-mediated blockade — research-grade anti-C1q antibodies (e.g., the investigational research antibody ANX005 used in preclinical neurodegeneration models) are used to acutely deplete or neutralize C1q in vivo, complementing genetic knockout approaches for temporal control.
• •Recombinant globular head fragments — isolated gC1q domains are used to dissect receptor-specific signaling (e.g., LAIR-1 engagement) independent of the full collagen-stalk-dependent C1r/C1s activation.

Summary Table: Key C1q Research Facts

Research Use Only Disclaimer

This article is provided for educational and laboratory research purposes only. C1q, related complement proteins, and any antibodies or reagents referenced are Research Use Only (RUO) materials intended for in vitro and preclinical research applications. Nothing in this article constitutes medical advice, a treatment protocol, or a claim of therapeutic efficacy for any human or animal condition. Always consult primary literature and institutional research guidelines before designing experiments involving complement pathway reagents.

Common Pitfalls in C1q Research

• •Confusing complement-dependent and complement-independent C1q effects. Many of C1q's non-canonical functions (LAIR-1 signaling, tumor microenvironment effects, apoptotic cell tethering) occur without C1r/C1s proteolysis. Experiments aiming to isolate "classical pathway activation" specifically should include C4/C3 cleavage readouts, not just C1q binding or C1q knockout phenotypes alone.
• •Serum vs. locally synthesized C1q. Circulating (largely macrophage-derived) C1q and tissue-resident, locally synthesized C1q (e.g., from microglia or tumor-associated stroma) can have distinct — sometimes opposing — functional consequences. Bone-marrow chimera or conditional knockout designs are often necessary to distinguish systemic from local C1q contributions.
• •Age and sex as confounders in CNS studies. Because C1q accumulates so steeply with age, synaptic-pruning and neurodegeneration-model studies must carefully age-match cohorts; a modest difference in animal age can produce large, confounding differences in baseline C1q burden independent of the experimental manipulation.
• •CR3 vs. other phagocytic receptors. Not all C1q/C3-tagged engulfment proceeds through microglial CR3 (CD11b/CD18) — some studies report CR3-independent phagocytic pathways, so CR3 blockade alone should not be assumed sufficient to fully abrogate complement-mediated synaptic engulfment in every model system.

Frequently Asked Questions

Is C1q the same as C1?

No. C1q is the recognition subunit; the full C1 complex is C1q non-covalently bound to two molecules each of the C1r and C1s serine protease zymogens (C1qC1r₂C1s₂). C1q alone has no proteolytic activity.

Does C1q require antibody binding to function?

Not always. While antibody-antigen complexes are the canonical classical-pathway trigger, C1q also directly recognizes apoptotic cell surfaces, certain pentraxins, and fibrillar protein aggregates independent of immunoglobulin, and several of its receptor-mediated effects (e.g., via LAIR-1) do not require antibody engagement at all.

Why is C1q relevant to Alzheimer's disease research models specifically, rather than neurodegeneration broadly?

The strongest mechanistic data — pre-plaque synaptic C1q tagging, protection from synapse loss upon C1q/C3 blockade — comes from amyloid-precursor-protein transgenic mouse models. Analogous complement-tagging mechanisms are actively being investigated in tauopathy and synucleinopathy models, but the causal evidence base is currently most mature in amyloid-model systems.

What distinguishes C1q from mannose-binding lectin (MBL) experimentally?

Both are collagen-domain-containing oligomeric pattern-recognition molecules that activate downstream complement pathways, but they are genetically and structurally distinct, engage different associated proteases (C1r/C1s for C1q vs. MASP-1/MASP-2 for MBL), and recognize different ligand classes (immune complexes/apoptotic cells vs. microbial carbohydrate patterns).